Current Edition

ABBVIE

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

For years, AbbVie’s business has relied on Humira. One of the world’s top-selling medicines, Humira brought in close to $20 billion for AbbVie in each …

Continue Reading →
ABBVIE

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …

Continue Reading →